U.S. tariffs on Canadian drugs could send prices soaring and leave pharmacy shelves empty, threatening access to antibiotics, HIV treatments, and more.
Published on April 1, 2025, in The Journal of the American Medical Association (JAMA), this research unpacks the fallout of President Donald Trump’s proposed 25% tariff, set to hit on April 2.
From life-saving meds sole-sourced from Canada to fragile supply chains, the stakes are sky-high.
Here’s why this could spark a healthcare nightmare—and what it means for you.
Table of Contents
The Tariff Threat: A $750 Million Gamble on Canadian Drugs
Picture this: you head to the pharmacy for antibiotics, only to find they’re out of stock or cost double.
That’s the grim future the JAMA study predicts if U.S. tariffs disrupt Canadian drug imports.
Led by Mina Tadrous, a University of Toronto drug policy expert and pharmacist, the research dives into a year of U.S. data (Q4 2022 to Q3 2023) and finds Canada’s role in the drug market is small but mighty.
Canadian-made drugs make up just 2% of U.S. sales—$3 billion annually—but a 25% tariff would slap on an extra $750 million in costs.
That’s no small change, and it’s unlikely drug companies will eat it.
Instead, patients could see higher prices and shortages, especially for critical medications like:
Ibalizumab: A key HIV treatment with no U.S. alternative.
Oxcarbazepine: A seizure-prevention drug sole-sourced from Canada.
Antibiotics and antidepressants: Everyday essentials at risk.
“Tariffs could block access to drugs where Canada’s the only supplier,” Tadrous warns.
“This hits infections, chronic conditions—everything.”
Trump’s Plan: Boost Jobs, Slash Canadian Drug Prices?
Donald Trump’s tariff push, branded “Liberation Day” for American trade, kicks off April 2, 2025. The goal?
Boost U.S. manufacturing and tackle sky-high drug prices.
It’s a bold pitch—America-first pharma sounds great on paper.
But the JAMA study suggests it’s a gamble that could backfire.
Historically, tariffs don’t guarantee cheaper goods.
Look at the 2018 steel tariffs: costs spiked, and consumers paid more. Drugs could follow the same path.
The U.S. gets 22,000 individual drug products (think different brands and doses of 3,100 unique drugs), and Canada supplies 411 of them.
That’s a niche but vital lifeline—$3 billion worth—that tariffs could choke.
“Both countries could lose,” Tadrous cautions.
“Higher costs and supply chain chaos don’t respect borders.”
Canada’s even mulling counter-tariffs, turning this into a potential trade war with pills as the ammo.
The Data: Canada’s Critical Role
Let’s break it down.
The U.S. drug market is massive—22,000 products strong, representing 3,100 unique drugs.
A “unique drug” is the core medicine (e.g., ibuprofen), while “individual products” are its forms (e.g., Advil tablets or Motrin gelcaps).
Canada’s 411 products might seem minor, but the details are chilling:
173 unique drugs (5.6%) use Canadian ingredients.
52 drugs (1.7%) rely heavily on Canada for supply.
28 drugs are sole-sourced from Canada—no backup exists.
27 drugs have a shortage history.
23 drugs are “clinically important”—top treatments experts swear by.
That 2% market share? It’s $3 billion of must-have meds.
A $750 million tariff hit could ripple fast, especially for generics with thin margins.
“Small supply shifts spark big shortages,” the study notes.
“Manufacturers can’t scale up overnight.”
Sole-Sourced Drugs: The Weak Link
Sole-sourced drugs are the ticking time bomb.
Take Ibalizumab: it’s a last-resort HIV treatment for patients with multidrug-resistant strains. Canada’s the only supplier.
If tariffs disrupt that flow, there’s no substitute waiting in the wings.
Same goes for Oxcarbazepine, a go-to for epilepsy patients. One hiccup, and seizures spike.
Then there’s antibiotics—already a global shortage headache.
The U.S. leans on Canada for key versions.
Tariffs could turn a tight supply into a crisis, fueling superbugs as infections go untreated.
“These aren’t optional drugs,” Tadrous says.
“They’re lifelines.”
Brand vs. Generic: Who Takes the Hit?
Not all drugs will feel the pain equally.
The study predicts brand-name drugs—think high-cost HIV meds—might absorb the tariff short-term, passing costs to insurers or patients later.
Generics, though?
They’re the wild card.
Cheaper and less flexible, they’re prone to shortages when costs climb.
Long-term effects?
“Uncertain,” the study admits, but history isn’t kind—think 2020’s COVID-driven drug droughts.
For patients, this isn’t theoretical.
A $20 generic could jump to $25—or vanish.
A $1,000 brand-name dose might creep higher, straining budgets.
And with 27 at-risk drugs already shortage-prone, the clock’s ticking.
Supply Chain Fragility: A House of Cards
Drug supply chains aren’t built for shocks.
The JAMA study flags a brutal truth: “Minor disruptions create shortages.”
Why?
Pharma’s a global web—Canada makes the pills, India supplies the raw stuff, the U.S. packages it.
Tariffs throw a wrench in that machine.
Canadian firms might cut exports if profits tank, and U.S. factories can’t fill the gap fast.
Remember the pandemic?
Masks, ventilators, meds—all ran dry when supply chains flinched.
Drugs like antibiotics or antidepressants could be next.
“Scalability’s the issue,” Tadrous explains.
“You can’t flip a switch and make more.”
Canada Strikes Back: A Trade War Looms
Canada’s not rolling over.
If the U.S. tariffs hit, policymakers are eyeing retaliation—counter-tariffs on U.S. drugs.
It’s a classic tit-for-tat spiral, and history shows these rarely end well.
The 1930s Smoot-Hawley tariffs tanked trade and deepened the Depression.
Today, a pharma feud could hike costs and cut supply on both sides.
“Counter-tariffs strain everything further,” Tadrous warns.
“It’s counterproductive—a dangerous precedent.”
The USMCA trade deal once kept drugs tariff-free, but “Liberation Day” could shred that safety net.
The Human Toll: Patients in the Crossfire
This isn’t just numbers—it’s people.
A Texas dad needs antibiotics for his kid’s strep throat.
A Chicago woman relies on Ibalizumab to fight HIV.
A Seattle retiree takes Oxcarbazepine to dodge seizures.
Tariffs don’t care—they hit hard and wide.
HIV patients: No Ibalizumab? Treatment fails, health crashes.
Epilepsy sufferers: Oxcarbazepine shortages mean more fits, more ER trips.
Everyday folks: Antibiotic gaps breed resistant bugs.
The 23 “clinically important” drugs are the backbone of modern care.
Disrupt them, and doctors scramble.
The 27 with shortage histories?
They’re already teetering.
Add a tariff, and it’s game over.
Beyond Canada: A Global Domino Effect
Canada’s a small player—2% of the U.S. market.
China, India, and Europe dwarf it, supplying 40-50% of generics.
If Trump’s tariff fever spreads, the fallout could be apocalyptic.
India’s penicillin, China’s insulin, Europe’s cancer drugs—all could face levies, jacking up costs and slashing supply.
“Extending tariffs to bigger suppliers amplifies this,” the study warns.
“Exempting pharma avoids a healthcare cost explosion.”
One misstep, and the U.S. could face a drug crisis bigger than anything since COVID.
Trump’s Vision vs. Reality
Trump’s betting tariffs will force drugmakers stateside, slashing prices and adding jobs.
It’s a patriotic pitch—but the U.S. isn’t ready.
Building pharma plants takes years, not weeks.
Meanwhile, Canada’s $3 billion supply keeps patients alive.
Cut that off, and the gap’s glaring.
Past tariffs—like 2018’s steel levies—didn’t spark a manufacturing boom; they raised prices. Drugs could mirror that.
“Lower prices sound nice,” Tadrous says, “but this could make them climb instead.”
What’s Next? April 2 Looms
“Liberation Day” hits April 2, 2025—just days away.
Will they deliver jobs and savings, or empty shelves and sticker shock?
The JAMA study leans grim: higher costs, tighter supply, and a healthcare system on edge.
Patients, pharmacies, and hospitals are bracing.
Stockpiling’s an option, but not for everyone.
“Policymakers should rethink this,” Tadrous urges.
“Health shouldn’t be a trade war pawn.”
Why This Matters to You
Your meds could cost more—or vanish—by next week.
Antibiotics for a cold, HIV drugs to live, antidepressants to cope: tariffs touch them all.
The U.S. and Canada are neighbors, not enemies—why risk this?
Share this, dig deeper, and speak up. April 2’s coming fast.
Stay updated with CTC news.
